As of 2025-07-16, the Intrinsic Value of NeuBase Therapeutics Inc (NBSE) is -18.31 USD. This NBSE valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.38 USD, the upside of NeuBase Therapeutics Inc is -4,943.03%.
Based on its market price of 0.38 USD and our intrinsic valuation, NeuBase Therapeutics Inc (NBSE) is overvalued by 4,943.03%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -18.31 - -18.31 | -18.31 | -4,943.03% |
| P/E | (2.93) - (47.96) | (26.00) | -6977.1% |
| DDM - Stable | (27.59) - (84.80) | (56.20) | -14966.7% |
| DDM - Multi | (2.82) - (6.79) | (3.99) | -1154.8% |
| Market Cap (mil) | 1.42 |
| Beta | 1.55 |
| Outstanding shares (mil) | 3.75 |
| Enterprise Value (mil) | -11.15 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.59% |
| Cost of Debt | 5.00% |
| WACC | 10.22% |